Coya Therapeutics, Inc. (COYA) - 10-K Summary
Business Context and Reporting Period
Company: Coya Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Coya is a clinical-stage biotechnology company developing therapies to enhance the function of regulatory T cells (Tregs) to treat neurodegenerative, autoimmune, and metabolic diseases. The company operates three therapeutic modalities: Treg-enhancing biologics (300 Series), Treg-derived exosomes (200 Series), and autologous Treg cell therapy (100 Series).
Key Asset: COYA 302, a combination biologic of low-dose IL-2 (COYA 301) and CTLA4-Ig, is the lead asset currently in development for Amyotrophic Lateral Sclerosis (ALS), with expansion plans for Frontotemporal Dementia (FTD), Parkinson's Disease (PD), and Alzheimer's Disease (AD).
Key Financial Metrics
| Metric (in millions) | 2024 | 2023 |
|---|---|---|
| Collaboration Revenue | $3.6 | $6.0 |
| Net Loss | $(14.9) | $(8.0) |
| Research & Development Expenses | $11.9 | $5.5 |
| General & Administrative Expenses | $8.9 | $7.8 |
| Cash and Cash Equivalents (Year End) | $38.3 | $32.6 |
| Accumulated Deficit | $(40.7) | $(25.9) |
Liquidity: As of December 31, 2024, the company held $38.3 million in cash and cash equivalents. Management expects these funds to support operations into 2026. The company has no debt and no credit facilities.
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased by approximately $2.4 million (40%) from $6.0 million in 2023 to $3.6 million in 2024. This was primarily due to the recognition of a $6.0 million license fee in 2023 upon the delivery of the license under the Dr. Reddy's Laboratories (DRL) agreement, whereas 2024 revenue consisted mainly of R&D services and a catch-up adjustment from a contract amendment.
- Increased Operating Loss: Net loss increased by $6.9 million, driven by a $6.4 million increase in R&D expenses. The rise in R&D costs reflects increased preclinical activities ($5.0 million increase) and internal R&D expenses ($1.1 million increase) to advance COYA 302 toward an Investigational New Drug (IND) filing.
- Financing Activity: In 2024, the company raised approximately $14.0 million in net proceeds from two private placements (May and October 2024) and $2.1 million from warrant exercises. In 2023, financing was dominated by a $24.0 million private placement and the IPO.
Guidance, Outlook, and Risks
Outlook and Milestones:
- COYA 302 (ALS): The company intends to file an IND for a Phase 2 clinical trial in the second quarter of 2025, following the completion of required nonclinical toxicology studies requested by the FDA in late 2024.
- Pipeline Expansion: In January 2025, the company announced COYA 303, a new investigational biologic combining COYA 301 with a GLP-1 receptor agonist for inflammatory diseases. Preclinical data showed synergistic anti-inflammatory effects.
- COYA 301 (AD): Positive results were announced in February 2025 from an investigator-initiated Phase 2 study in Alzheimer's Disease, showing cognitive stabilization and improved biomarkers with a monthly dosing regimen.
Management Commentary: Management views COYA 302 as a "Pipeline in a Product" due to its potential across multiple neurodegenerative indications. The company is actively pursuing partnerships to leverage COYA 301 as a backbone therapy.
Risks and Contingencies:
- Going Concern: While cash is sufficient for 2026, the company expects to incur significant losses and will require substantial additional capital to fund clinical trials and commercialization. Failure to raise capital could force delays or discontinuation of programs.
- Regulatory Uncertainty: The FDA has requested additional nonclinical data for COYA 302 before allowing the Phase 2 trial to proceed. There is no assurance the FDA will accept the data or approve the trial on the proposed timeline.
- Preclinical Toxicity: In preclinical studies of COYA 201 (exosomes), fatalities were observed in animals at extremely high doses (10x the low dose). While the low dose was well-tolerated, this highlights the need for careful dose selection in future human trials.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $38.3 million cash balance against the projected burn rate for 2025-2026, specifically considering the costs of the upcoming Phase 2 IND-enabling studies.
- IND Filing Timeline: Monitor the company's progress in completing the FDA-requested nonclinical toxicology studies for COYA 302 to confirm the Q2 2025 IND filing target.
- COYA 301 Dosing Regimen: Review the full data from the Alzheimer's Disease study to confirm the superiority of the monthly (q4wks) dosing regimen over the biweekly regimen regarding Treg functionality and cognitive outcomes.
- Dr. Reddy's Collaboration: Track the status of the $4.2 million milestone payments due upon IND acceptance and first patient dosing, and monitor the execution of the commercial supply agreement.
- Preclinical Safety: Assess the implications of the high-dose toxicity observed in COYA 201 animal models for the safety profile of the exosome platform in humans.